Resverlogix Corp. (RVX : TSX)
Common Stock
Follow RVX
RVX
Resverlogix Corp.
Performance
1 Day
+0.00%
1 Week
-6.25%
1 Month
-6.25%
YTD
-25.00%
The Tuesday Stock Pick · free, every tuesday morning. One Canadian stock and the case for it.
Key Statistics
Market Cap
$27.54M
52W High
$0.15
52W Low
$0.06
P/E Ratio
-
50 Day MA
$0.09
200 Day MA
$0.10
Beta
0.96
Dividend Yield
-
Performance history
RVX returns since 2023
Resverlogix Corp. has traded since Nov 2023 in our data, with 1 up year out of 2 full calendar years. Its deepest fall was −69.6% (Jul 2025 to Nov 2026).
1 year / yr
−25.0%
3 years / yr
+2.3%
5 years / yr
—
10 years / yr
—
Calendar-year returns
- 2023*0.0%
- 2024−14.3%
- 2025+66.7%
- 2026*−25.0%
* Partial year (first year of data, or year to date).
$10,000 invested in RVX
- 1 year ago$7,500
- 2023 (start of our data)$10,714
- Best year
- 2025: +66.7%
- Worst year
- 2024: −14.3%
- All-time high in our data
- $0 on Jul 22, 2025 · now −67.4%
Total-return basis using adjusted daily closes from the Toronto Stock Exchange and TSX Venture (dividends and splits folded in), Nov 2023 to Nov 2026. Past returns do not predict future ones.
Earnings
RVX earnings history
Resverlogix Corp.'s reported EPS by quarter.
| Quarter ending | Reported | EPS | Estimate | Surprise |
|---|---|---|---|---|
| Jun 30, 2026 | Aug 13, 2026 | −$0.03 | — | — |
| Mar 31, 2026 | May 14, 2026 | −$0.02 | — | — |
| Dec 31, 2025 | Mar 31, 2026 | −$0.00 | — | — |
| Sep 30, 2025 | Nov 12, 2025 | −$0.00 | — | — |
| Jun 30, 2025 | Aug 14, 2025 | −$0.01 | — | — |
| Mar 31, 2025 | Jun 4, 2025 | −$0.03 | — | — |
| Dec 31, 2024 | Dec 31, 2024 | $0.00 | — | — |
| Sep 30, 2024 | Nov 7, 2024 | −$0.02 | — | — |
EPS as reported vs consensus estimate. TSX earnings calendar →
Awesome Portfolio™
Looking past RVX? Our 10 best Canadian stocks, in one list.
14.8% a year since 2017 against 9.7% for the S&P/TSX Composite (+5.0 points a year). Reviewed every month.
Technical Indicators
Price vs 50-Day SMA
Price vs 200-Day SMA
Recent Price History
| Date | Open | High | Low | Close | Adj Close | Volume |
|---|---|---|---|---|---|---|
| 11/16/2026 | $0.07 | $0.07 | $0.07 | $0.07 | $0.07 | 129,000 |
| 11/13/2026 | $0.07 | $0.07 | $0.07 | $0.07 | $0.07 | 36,000 |
| 11/12/2026 | $0.07 | $0.07 | $0.07 | $0.07 | $0.07 | 7,689 |
| 11/11/2026 | $0.08 | $0.08 | $0.08 | $0.08 | $0.08 | 0 |
| 11/10/2026 | $0.08 | $0.08 | $0.08 | $0.08 | $0.08 | 5,000 |
| 11/9/2026 | $0.07 | $0.08 | $0.07 | $0.08 | $0.08 | 70,380 |
| 11/6/2026 | $0.07 | $0.08 | $0.07 | $0.07 | $0.07 | 46,600 |
| 11/5/2026 | $0.07 | $0.07 | $0.06 | $0.07 | $0.07 | 216,400 |
| 11/4/2026 | $0.08 | $0.08 | $0.07 | $0.08 | $0.08 | 64,011 |
| 11/3/2026 | $0.08 | $0.08 | $0.07 | $0.07 | $0.07 | 2,850 |
Analyst Price Targets
Based on analyst covering RVX · as of Sep 17, 2026
Wall Street analysts forecast RVX stock price to rise 10166.7% over the next 12 months.
Consensus
BullishBased on avg. target vs last close (formal rating unavailable for Canadian listings)
Avg. Target
C$7.70
+10166.7% Upside
Current Price
C$0.07
Last close
Targets are snapshotted when they change. Unchanged figures keep their original date. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on RVX's historical volatility
30-Day Vol
87.5%
Annualized
90-Day Vol
78.6%
Annualized
Trend (90d)
-50.0%
Annualized drift
90d Mean
C$0.06
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | C$0.07 | C$0.05 – C$0.10 |
| 60 trading days | C$0.07 | C$0.04 – C$0.10 |
| 90 trading days | C$0.06 | C$0.04 – C$0.11 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
About Resverlogix Corp.
Resverlogix Corp., a late-stage clinical biotechnology company, develops therapeutics for patients with chronic illnesses. Its lead drug is apabetalone (RVX-208), a small molecule selective bromodomain and extra-terminal inhibitor for patients with cardiovascular disease, chronic kidney disease, type 2 diabetes mellitus, low high-density lipoprotein, recent acute coronary syndrome, and post COVID-19 conditions. The company has a partnership with Eversana Life Science Services, LLC to support the commercialization of apabetalone for COVID-19 in the United States and Canada; developing cardiovascular and pulmonary arterial hypertension indications; and Medison Pharma Ltd. The company is headquartered in Calgary, Canada.
Financials
- Revenue (TTM)
- $0
- EBITDA
- $-4.77M
- Profit Margin
- 0.00%
- ROE (TTM)
- 0.00%
- EPS (Diluted)
- -0.04
- Book Value
- -0.38
Classification
- Sector
- Health Care
- Industry
- Biotechnology
- Group
- Pharmaceuticals, Biotechnology & Life Sciences
Free newsletter
The Tuesday Stock Pick
One Canadian stock and the case for it
- The name with the biggest gap to analyst targets
- The chart, insider buying and what is driving it
- A plain-English bottom line, no hype
Explore More
Common Questions About RVX
Market movers
Recent TSX movers
Top 1-day gainers — updated from our Canadian movers feed.
| Ticker | Name | Price | 1D |
|---|---|---|---|
| HWO | High Arctic Energy Services Inc. | $1.74 | +29.85% |
| AAV | Advantage Oil & Gas Ltd. | $13.45 | +23.74% |
| LUC | Lucara Diamond Corp | $0.13 | +13.64% |
| T | Telus Corp | $13.70 | +12.85% |
| FRX | Fennec Pharmaceuticals Inc | $18.35 | +10.81% |
| KEL | Kelt Exploration Ltd. | $12.72 | +10.70% |
| NVO | Novo Resources Corp | $0.07 | +8.33% |
| ELO | Eloro Resources Ltd. | $1.23 | +7.89% |
Free with a Wealth Awesome account
Keep analysing RVX, free
- Every WA Score, ranking and table
- Insider track records and SEDI filings
- Earnings history and analyst targets for every stock
Email only, no password, no card. Already a member? Use the same button to sign in.
